Variability in the Definition and Reporting of Adverse Events in Suicide Prevention Trials: An Examination of the Issues and a Proposed Solution

被引:6
作者
Oquendo, Maria A. [1 ]
Feldman, Sarah [1 ]
Silverman, Emily [1 ]
Currier, Dianne [2 ]
Brown, Gregory K. [3 ]
Chen, Donna [4 ]
Chiapella, Page [5 ]
Fischbach, Ruth [1 ]
Gould, Madelyn [1 ]
Stanley, Barbara [1 ]
Strauss, David [1 ]
Zelazny, Jamie [6 ]
Pearson, Jane [7 ]
机构
[1] New York State Psychiat Inst & Hosp, New York, NY 10032 USA
[2] Columbia Univ, Dept Psychiat, New York, NY USA
[3] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA
[4] Univ Virginia, Ctr Biomed Eth & Humanities, Charlottesville, VA USA
[5] NIAAA, Bethesda, MD USA
[6] Univ Pittsburgh, Pittsburgh, PA USA
[7] NIMH, Bethesda, MD 20892 USA
关键词
Adverse Events; safety; Serious Adverse Events; study evaluation; suicide research; TOWER-OF-BABEL; CLINICAL-TRIALS; SAFETY; INTERVENTION; NOMENCLATURE; MULTICENTER; IMPROVEMENT; BEHAVIOR; LESSONS; CARE;
D O I
10.1080/13811118.2011.541146
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Adverse events (AEs) and serious adverse events (SAEs) are important outcomes of any intervention study yet are under-researched. Vague and variable definitions and substantial underreporting make comparisons of risk between studies difficult and evaluation of the safety of a particular intervention almost impossible. These realities may deter researchers from studying at-risk populations. Suicidal behavior is an adverse event in any study, and potentially a very serious one. Thus the issues of reporting and definition are particularly salient for researchers who work with populations at risk for suicidal behavior, especially when the suicidal behavior is the outcome of interest. We conducted a qualitative study with experienced suicide researchers and intervention experts to delineate the issues related to reporting serious adverse events faced by investigators conducting trials in suicide prevention. Participants from multiple sites were interviewed by phone, interviews transcribed and coded for definition and reporting issues and suggested solutions. A narrative synthesis was prepared and validated by all participants. Participants highlighted the difficulties in defining AEs and SAEs and stressed the importance and complexity of ensuring the AE was related to the study and reported properly, and were in agreement about the consequences of AEs to both institutions and individuals. Participants identified the need for the development of clear and consistent AE definitions and reporting requirements. Clear and consistently applied definitions of adverse and serious adverse events and reporting requirements would enhance the comparability of intervention studies in suicidal populations.
引用
收藏
页码:29 / 42
页数:14
相关论文
共 50 条
  • [21] Incomplete reporting of adverse events in duloxetine trials: a meta-research survey of randomized controlled trials vs placebo
    Rolland, P.
    Jutel, A.
    Douget, K.
    Naudet, F.
    Roy, J. C.
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2025, 180
  • [22] Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
    Kim, Tae-Hun
    Birch, Stephen
    Alraek, Terje
    Lee, Myeong Soo
    INTEGRATIVE MEDICINE RESEARCH, 2023, 12 (03)
  • [23] Reporting of data monitoring committees and adverse events in paediatric trials: a descriptive analysis
    Gates, Allison
    Caldwell, Patrina
    Curtis, Sarah
    Dans, Leonila
    Fernandes, Ricardo M.
    Hartling, Lisa
    Kelly, Lauren E.
    Vandermeer, Ben
    Williams, Katrina
    Woolfall, Kerry
    Dyson, Michele P.
    BMJ PAEDIATRICS OPEN, 2019, 3 (01)
  • [24] Measuring and reporting adverse events in clinical trials of psychological treatments for chronic pain
    Palermo, Tonya M.
    Slack, Katherine
    Loren, Dorothy
    Eccleston, Christopher
    Jamison, Robert N.
    PAIN, 2020, 161 (04) : 713 - 717
  • [25] Reporting of adverse events in randomised controlled trials of antiepileptic drugs using the CONSORT criteria for reporting harms
    Shukralla, Arif A.
    Tudur-Smith, Catrin
    Powell, Graham A.
    Williamson, Paula R.
    Marson, Anthony G.
    EPILEPSY RESEARCH, 2011, 97 (1-2) : 20 - 29
  • [26] The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors
    Karimian, Zahra
    Mavoungou, Sandra
    Salem, Joe-Elie
    Tubach, Florence
    Dechartres, Agnes
    BMC CANCER, 2020, 20 (01)
  • [27] Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events
    Mayo-Wilson, Evan
    Fusco, Nicole
    Hong, Hwanhee
    Li, Tianjing
    Canner, Joseph K.
    Dickersin, Kay
    TRIALS, 2019, 20 (01)
  • [28] Opportunities for selective reporting of harms in randomized clinical trials: Selection criteria for non-systematic adverse events
    Evan Mayo-Wilson
    Nicole Fusco
    Hwanhee Hong
    Tianjing Li
    Joseph K. Canner
    Kay Dickersin
    Trials, 20
  • [29] The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors
    Zahra Karimian
    Sandra Mavoungou
    Joe-Elie Salem
    Florence Tubach
    Agnès Dechartres
    BMC Cancer, 20
  • [30] Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review
    Yuniar, Cindra Tri
    Pratiwi, Bhekti
    Ihsan, Ardika Fajrul
    Laksono, Bambang Tri
    Risfayanti, Iffa
    Fathadina, Annisa
    Jeong, Yeonseon
    Kim, Eunyoung
    VACCINES, 2022, 10 (02)